Literature DB >> 16998

Unusual alpha adrenergic receptor potency of methyldopa metabolites on melanocyte function.

W A Pettinger.   

Abstract

Catecholamines possessing alpha adrenergic receptor agonist properties induce lightening or reverse melanocyte stimulating hormone darkening of frog skin in vitro. The capacity to activate this alpha receptor by the methyldopa metabolites methyldopamine and methylnorepinephrine was compared with the capacity of the naturally occurring dopa metabolites, dopamine and norepinephrine. Melanocyte stimulating hormone-induced darkening or dispersion of the granules was reversed by each of these metabolites. Methylnorepinephrine was 10 times as potent as norepinephrine, and methyldopamine was 30- to 100-fold more potent than the naturally occurring dopamine. These inhibitory effects on melanocyte stimulating hormone could be blocked or partially impaired using the alpha adrenergic blocker, phentolamine. They were not affected by pretreatment of frogs with the monoamine oxidase inhibitor pheniprazine (Catron) nor by the application of pheniprazine, angiotensin or serotonin in vitro. This neuroendocrine model has alpha adrenergic receptor relationships analogous to those described in the central nervous system for methyldopa metabolites.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 16998

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  The characteristics of [3H]-clonidine binding to an alpha-adrenoceptor in membranes from guinea-pig kidney.

Authors:  B Jarrott; W J Louis; R J Summers
Journal:  Br J Pharmacol       Date:  1979-04       Impact factor: 8.739

2.  The association between the melanocyte-stimulating hormone receptor and the alpha 2-adrenoceptor on the Anolis melanophore.

Authors:  R J Carter; S Shuster
Journal:  Br J Pharmacol       Date:  1982-01       Impact factor: 8.739

Review 3.  α 2-Adrenoceptors: Challenges and Opportunities-Enlightenment from the Kidney.

Authors:  William A Pettinger; Edwin K Jackson
Journal:  Cardiovasc Ther       Date:  2020-04-29       Impact factor: 3.023

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.